<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: In the present study, we investigated whether systemic pretreatment with the AT1 receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, <z:chebi fb="0" ids="3347">candesartan</z:chebi>, reduces neuronal injury after <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> in rats </plain></SENT>
<SENT sid="1" pm="."><plain>DESIGN AND METHODS: Focal <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> in male, normotensive Wistar rats was induced by 90 min middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) followed by reperfusion </plain></SENT>
<SENT sid="2" pm="."><plain>Experiment 1: <z:chebi fb="0" ids="3347">Candesartan</z:chebi> was injected intravenously (i.v.) at doses of 0.1 or 0.3 mg/kg, 4 h prior to ischaemic injury </plain></SENT>
<SENT sid="3" pm="."><plain>Experiment 2: Rats were treated with <z:chebi fb="0" ids="3347">candesartan</z:chebi> [0.1 mg/kg, subcutaneously (s.c.) twice daily], on 5 consecutive days prior to <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The last injection was administered 12 h before MCAO </plain></SENT>
<SENT sid="5" pm="."><plain>Mean arterial pressure (MAP) was measured before, during and after ischaemic injury </plain></SENT>
<SENT sid="6" pm="."><plain>Twenty-four hours after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>, neurological outcome, <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and <z:hpo ids='HP_0002181'>brain oedema</z:hpo> were evaluated </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: <z:hpo ids='HP_0011009'>Acute</z:hpo> i.v. pretreatment with <z:chebi fb="0" ids="3347">candesartan</z:chebi>, 0.1 and 0.3 mg/kg, dose-dependently <z:mp ids='MP_0004876'>decreased MAP</z:mp> before, during and after ischaemic injury but did not improve recovery from brain <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Systemic long-term s.c. pretreatment with 0.1 mg/kg <z:chebi fb="0" ids="3347">candesartan</z:chebi>, <z:mp ids='MP_0004876'>reduced MAP</z:mp> during and after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> to the same extent as did the i.v. dose of 0.1 mg administered 4 h before MCAO, but significantly improved neurological outcome and reduced infarction size and <z:hpo ids='HP_0000969'>oedema</z:hpo> of the ipsilateral hemisphere when compared with the vehicle-treated group </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: Long-term blockade of AT1 receptors improves neurological outcome of focal <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> and protects brain tissue against ischaemic injury </plain></SENT>
</text></document>